SLC6A2 and Parkinson disease: After exclusion from analysis of all data from patients on levodopa-carbidopa, droxidopa, or drugs known to inhibit the cell membrane norepinephrine transporter, statistical analyses were conducted for 20 patients with PD, 19 patients with PAF, 16 patients with MSA, and 17 controls.